Completed PHASE1 INTERVENTIONAL 1-arm NCT01809860

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects

Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Healthy Subjects Pharmacokinetics of Isavuconazole Pharmacokinetics of Sirolimus

Interventions isavuconazole sirolimus

Updated 5 times since 2017 Last updated: Mar 11, 2013 Started: Nov 30, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01809860, this PHASE1 trial focuses on Healthy Subjects and Pharmacokinetics of Isavuconazole and remains completed. Sponsored by Astellas Pharma Global Development, Inc., it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States